首页> 美国卫生研究院文献>Globalization and Health >Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP

【2h】

Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP

机译：全球伙伴关系在发展中国家获取药物的好处：对患者和GIPAP中患者结果的多国分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundAccess to medicines in developing countries continues to be a significant problem due to lack of insurance and lack of affordability. Chronic Myeloid Leukemia (CML), a rare disease, can be treated effectively, but the pharmaceutical treatment available (imatinib) is costly and unaffordable by most patients. GIPAP, is a programme set up between a manufacturer and an NGO to provide free treatment to eligible CML patients in 80 countries worldwide.

机译：背景技术由于缺乏保险和负担能力，在发展中国家获得药品仍然是一个重大问题。慢性粒细胞白血病（CML）是一种罕见的疾病，可以有效治疗，但可用的药物治疗（imatinib）昂贵且大多数患者无法负担。 GIPAP是制造商和非政府组织之间建立的一项计划，旨在为全球80个国家/地区的合格CML患者提供免费治疗。

著录项

期刊名称 Globalization and Health
作者
Panos Kanavos; Sotiris Vandoros; Pat Garcia-Gonzalez;
展开▼
作者单位

展开▼
年(卷),期 2009(5),-1
年度 2009
页码 19
总页数 13
原文格式 PDF
正文语种
中图分类公共卫生工程;
关键词

相似文献

外文文献
中文文献
专利

1. Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP [J] . Panos Kanavos, Sotiris Vandoros, Pat Garcia-Gonzalez Globalization and Health . 2009,第5期

机译：全球伙伴关系在发展中国家获取药物的好处：对患者和GIPAP患者结局的多国分析
2. Framing access to medicines in developing countries: an analysis of media coverage of Canada's Access to Medicines Regime [J] . Laura C Esmail, Kaye Phillips, Victoria Kuek, BMC International Health and Human Rights . 2010,第1期

机译：发展中国家获取药品的途径：对加拿大药品获取制度的媒体报道分析
3. Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized Medicine [J] . Leyens Lada, Richer Etienne, Melien Oyvind, Public health genomics . 2015,第5期

机译：在欧盟和美国，促进早期患者使用药物的可用工具：有条件批准的分析及其对个性化药物的影响
4. Protocol Feasibility Workflow Using an Automated Multi-country Patient Cohort System [C] . Inaki SOTO-REY, Benjamin TRINCZEK, Toresin KARAKOYUN, European Federation for Medical Informatics., Conference . 2014

机译：协议可行性工作流程使用自动多国患者队列队列系统
5. Globalisation and corporate governance in developing countries (a micro analysis of global corporate interconnection between developing African countries and developed countries) (Nigeria, Ghana). [D] . Ahunwan, Boniface U. 2002

机译：发展中国家的全球化和公司治理（对非洲发展中国家和发达国家之间全球公司相互联系的微观分析）（尼日利亚，加纳）。
6. The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: The Glivec International Patient Assistance Program (GIPAP) [O] . Chukwuemeka A. Umeh, Pat Garcia-Gonzalez, David Tremblay, 2020

机译：参与全球直接面向患者的癌症药物捐赠计划的患者的生存：Glivec国际患者援助计划（GIPAP）
7. Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP [O] . Vandoros Sotiris, Kanavos Panos, Garcia-Gonzalez Pat 2009

机译：全球伙伴关系在发展中国家获取药物的好处：对患者和GIPAP中患者结果的多国分析

Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP

摘要

著录项

相似文献

相关主题

期刊订阅